Expected data readouts in 2025, filling the unmet need, and estimated market opportunity in Oncology, Immunological and Neurodegenerative Diseases
In the evolving landscape of immunotherapy, Interleukin-2 (IL-2) therapies have carved a niche, particularly in the treatment of metastatic melanoma, metastatic renal cell carcinoma (mRCC), relapsed or refractory Peripheral T-cell Lymphoma (R/R PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (R/R CTCL). In addition to it, IL-2 therapies are now being vigorously explored across a wide range of disease areas, spanning oncology, autoimmune disorders, and beyond. Ongoing investigations include indications such as ...
